financetom
Business
financetom
/
Business
/
Targa Resources beats profit estimates on record gas volumes, boosts share buyback program
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Targa Resources beats profit estimates on record gas volumes, boosts share buyback program
Aug 7, 2025 6:49 AM

(Reuters) -Pipeline operator Targa Resources ( TRGP ) beat second-quarter adjusted core profit estimates, driven by record-high volumes of natural gas and natural gas liquids transported through its system.

The company also announced a new $1.0 billion share repurchase program in addition to its previous $1 billion plan.

Shares were up 2.6% at $167.32 in premarket trading.

Demand for natural gas has risen in recent quarters, driven by surging power demand from energy-hungry data centers and growing domestic consumption, helping firms like Targa, which transport natural gas.

In April, the U.S. Energy Information Administration said U.S. power consumption will hit new record highs in 2025 and 2026, on the back of data centers dedicated to AI and cryptocurrency.

The company's quarterly Permian natural gas inlet volumes rose about 11% to a record 6.28 billion cubic feet per day from a year earlier, while NGL pipeline transportation volumes surged about 23% also to a record 961,200 barrels per day.

The Houston, Texas-based company's adjusted core profit rose 18% to $1.16 billion for the quarter ended June 30, from a year earlier, beating analysts' average estimate of $1.14 billion, according to LSEG data.

Total revenue rose 20% to $4.26 billion, helped by higher NGL volumes and natural gas prices, though partially offset by lower NGL prices.

Targa supplies natural gas and NGLs to key markets through its network of gathering and processing assets across the Permian Basin, Eagle Ford Shale, Bakken Shale and other major U.S. oil and gas regions.

The company transports, processes and fractionates NGLs into component products like ethane, propane and butane.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
UnitedHealth Shareholders Call for Report to Evaluate Risks of Healthcare Denials
UnitedHealth Shareholders Call for Report to Evaluate Risks of Healthcare Denials
Jan 9, 2025
08:44 AM EST, 01/09/2025 (MT Newswires) -- UnitedHealth Group ( UNH ) shareholders have proposed that the health insurance company report on public health-related costs and macroeconomic risks caused by practices that limit or delay access to healthcare. The shareholder proposal said the report should evaluate how the company's practices impact access to healthcare and patient outcomes. It said the...
Equinox Gold Hits Record Q4 and Full-Year Gold Production
Equinox Gold Hits Record Q4 and Full-Year Gold Production
Jan 9, 2025
08:35 AM EST, 01/09/2025 (MT Newswires) -- Equinox Gold ( EQX ) reported overnight Wednesday record fourth-quarter gold production. Equinox produced 213,960 ounces of gold to bring the full year 2024 output to 621,870 ounces, the strongest quarterly and annual production in the company's history. The miner also met its 2024 annual production guidance of 590,000 to 675,000 ounces. Equinox...
American International Group Names Christopher Flatt Chief Underwriting Officer
American International Group Names Christopher Flatt Chief Underwriting Officer
Jan 9, 2025
08:41 AM EST, 01/09/2025 (MT Newswires) -- American International Group ( AIG ) said Thursday it has named Christopher Flatt as global chief underwriting officer, effective immediately. Flatt, who has been serving as head of North America Alternative Channels, will join the company's executive leadership team, the company said. He succeeds Christopher Schaper, who was appointed chief risk officer in...
Johnson & Johnson Says Nipocalimab Granted FDA Priority Review in Myasthenia Gravis
Johnson & Johnson Says Nipocalimab Granted FDA Priority Review in Myasthenia Gravis
Jan 9, 2025
08:44 AM EST, 01/09/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Thursday that the US Food and Drug Administration has granted priority review designation to its biologics license application for nipocalimab to treat antibody positive patients with generalized myasthenia gravis. The company said its application was supported by the results of a phase 3 study, which showed...
Copyright 2023-2026 - www.financetom.com All Rights Reserved